Office of the Dean
O’Dowd Hall, Room 428
586 Pioneer Drive
Rochester, MI 48309-4482
(map)
(248) 370-3634

Office Hours:
Monday – Friday: 8:00 a.m. – 5:00 p.m.

Rodney Nyland

Contact Information:

Office: 402 O’Dowd Hall
Phone: (248) 370-2874
nyland@oakland.edu


Specialties:

pharmacology, medicinal chemistry, cancer biology, molecular biology


Education:

Ph.D., Medicinal Chemistry and Molecular Pharmacology,
Purdue University, West Lafayette, Ind.,

B.S., Biomedical Sciences

B.S., Chemistry Grand Valley State University, Allendale, Mich.


Research interests:

Graduate education, anti-neoplastic drugs

Rodney Nyland II, Ph.D.
Assistant Professor of Biomedical Sciences specializing in Pharmacology


Rodney Nyland II

Dr. Nyland joined the Oakland University William Beaumont School of Medicine in September 2013 as an Assistant Professor of Biomedical Sciences, specializing in pharmacology. Prior to joining OUWB, Dr. Nyland was a founding faculty member at South College School of Pharmacy in Knoxville, Tenn., where he taught medicinal chemistry and pharmacology to pharmacy students and chaired the Technology Committee.

Dr. Nyland earned his B.S. degrees in Chemistry and Biomedical Sciences at Grand Valley State University, where his work synthesizing novel water-soluble Cisplatin anticancer agents with Drs. Miles Hacker, John Bender, and Robert Smart shifted his interests from organic chemistry to medicinal chemistry and pharmacology.

Dr. Nyland earned his Ph.D. in Medicinal Chemistry and Molecular Pharmacology at Purdue University. His research in Dr. Richard Borch’s laboratory at Purdue helped secure Dr. Nyland a pre-doctoral National Cancer Institute fellowship for his thesis work designing and synthesizing anticancer drugs and pro-drugs targeting apurinic endonuclease 1 (APE1).

He began his postdoctoral work with a fellowship in medicinal chemistry at the Auckland Cancer Society Research Centre (ACSRC) in Auckland, New Zealand. He then embarked on a two-and-a-half year postdoctoral fellowship at Johns Hopkins University in the School of Medicine, where Dr. Nyland designed and synthesized novel drugs targeting isoprenoid biosynthesis in malaria. During this time the National Cancer Institute awarded Dr. Nyland with an Anti-Cancer Drug Development Postdoctoral Fellowship to work on pro-drug strategies to deliver organodiphosphate drugs.

While organic and medicinal chemistry will always be a core interest of Dr. Nyland’s, his focus now is on scholarship within teaching and learning, including educational research focusing on developing novel instructional and technological techniques to facilitate student comprehension of complicated subject matter.